

ButyraGen®: New Clinical Evidence for Fast-Acting Belly Pain Relief and Enhanced Digestive Support in Women

Summary

ButyraGen® is an innovative, patent-pending prebiotic complex that directly generates butyrate, a key short-chain fatty acid (SCFA) known for supporting gut barrier integrity, reducing inflammation, and improving digestive comfort. In a newly published, randomized, double-blind, placebo-controlled clinical study, ButyraGen® demonstrated significant improvements in belly pain, gas, bloating, and overall digestive quality of life, particularly in women and post-menopausal women.¹

A Direct Source of Butyrate

ButyraGen® combines tributyrin, a triglyceride form of butyrate, with Sunfiber® (partially hydrolyzed guar gum), allowing it to generate butyrate independent of the state of the gut microbiome. Unlike dietary fiber that depends on bacterial fermentation, ButyraGen® releases butyrate through natural hydrolysis, ensuring a consistent and reliable daily supply.

New Peer-Reviewed Study Confirms Digestive Health Benefits

A 6-week, randomized, double-blind, placebo-controlled virtually conducted clinical study with a starting population of 595, conducted in a real-world setting, evaluated ButyraGen®'s effects on:

- Belly pain
- Gas and bloating
- Upper and lower GI symptoms
- Digestive quality of life (DQLQ)
- Tolerability and safety

Participants received 200 mg daily of ButyraGen® or placebo.




Figure 1. Temporal (week-to-week) changes in Belly Pain % participant improvement over the course of the 6-week study.

* $p < 0.05$, ** $p < 0.01$

Key Findings

- **Significant Belly Pain Relief**
 - ButyraGen® group had 18% greater improvement in belly pain vs. placebo ($p < 0.01$).
 - Improvements became significant by weeks 5–6, showing cumulative benefits.
- **Rapid Improvement in Quality of Life**
 - Participants with mild reflux or constipation experienced significant DQLQ improvements within 1–2 weeks.
 - 16.9%–18.8% greater improvement vs. placebo ($p < 0.05$).
- **Enhanced Benefits for Women**
 - Female participants had 20.3% greater belly pain improvement ($p < 0.01$) and a 14.9% reduction in gas/bloating vs. placebo.
 - Post-menopausal women saw the largest benefit: 26.4% greater improvement ($p < 0.05$) vs. placebo.
- **Excellent Tolerability**
 - Side effects were mild and similar to placebo; no serious adverse events reported.




Figure 2. Temporal (week-to-week) changes in DQLQ participant % improvement starting with normal or mild baseline reflux over the course of the 6-week study. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.005$

Participants with mild reflux or constipation also experienced rapid improvements in digestive quality of life (DQLQ) within one to two weeks, with a 16.9% to 18.8% greater improvement versus placebo ($p < 0.05$). Notably, women benefited even more, achieving a 20.3% greater reduction in belly pain ($p < 0.01$) and a 14.9% decrease in gas and bloating compared to placebo, while post-menopausal women experienced the greatest benefit, with a 26.4% greater improvement ($p < 0.05$). Importantly, ButyraGen® was well tolerated, with mild side effects comparable to placebo and no serious adverse events reported.




Figure 3. Temporal (week-to-week) changes in belly pain for females % participant improvement over the course of the 6-week study. * $p < 0.05$, ** $p < 0.01$.




Figure 4. Temporal (week-to-week) changes in female Belly Pain % participant improvement for women with self-reported post-menopausal over the course of the 6-week study. * $p < 0.05$

How ButyraGen® Works

- Tributyrin delivers butyrate directly, bypassing microbial fermentation variability.
- Butyrate reinforces the gut barrier, supports mucosal health, modulates motility, and calms inflammation, mechanisms linked to reductions in abdominal discomfort and improved gut function.^{2,4}
- Particularly supports women's gut health, which is impacted by hormonal changes, the estrobolome, and age-related shifts in gut motility and permeability.^{5,6}




Figure 5. Temporal (week-to-week) changes in female gas and bloating with GI distress % participant improvement over the course of the 6-week study. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.005$

Conclusions

This new study reinforces ButyraGen® as a novel, clinically substantiated, direct butyrate generator for digestive health. It delivers significant belly pain relief, fast symptom improvement, and unique benefits for women, with robust tolerability at a low daily dose.

References

1. Dosz E, Conley D, Lelah M. A Novel Direct Butyrate Generator Reduces Belly Pain in a Randomized, Double-Blind, Placebo-Controlled Clinical Study. *Nutraceuticals*. 2025; 5(2):14. <https://doi.org/10.3390/nutraceuticals5020014>
2. Hodgkinson K, El Abbar F, Dobranowski P, et al. Butyrate's role in human health and the current progress towards its clinical application to treat gastrointestinal disease. *Clin Nutr*. 2023;42(2):61-75. doi:10.1016/j.clnu.2022.10.024
3. Parada Venegas D, De la Fuente MK, Landskron G, et al. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases [published correction appears in *Front Immunol*. 2019 Jun 28;10:1486. doi: 10.3389/fimmu.2019.01486.1.
4. Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. *J Nutr*. 2009;139(9):1619-1625. doi:10.3945/jn.109.104638
5. Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: Physiological and clinical implications. *Maturitas*. 2017;103:45-53. doi:10.1016/j.maturitas.2017.06.025
6. Kim YS, Unno T, Kim BY, Park MS. Sex Differences in Gut Microbiota. *World J Mens Health*. 2020;38(1):48-60. doi:10.5534/wjmh.190009